U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C25H35NO5.ClH
Molecular Weight 466.01
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEBEVERINE HYDROCHLORIDE

SMILES

Cl.CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC2=CC=C(OC)C=C2

InChI

InChIKey=PLGQWYOULXPJRE-UHFFFAOYSA-N
InChI=1S/C25H35NO5.ClH/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5;/h9-14,18-19H,6-8,15-17H2,1-5H3;1H

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021

Mebeverine is an antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract. The exact mechanism of action is not known, but multiple mechanisms, such as a decrease in ion channel permeabilities, blockade of noradrenaline reuptake, a local anesthetic effects, as well as weak anti-muscarinic and phosphodiesterase inhibitory effect might contribute to the local effects of Mebeverine. This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Most people will not have problems with Mebeverine, but some may get some side effects, such as: difficulty in breathing, swelling of face, neck, tongue or throat, skin rash, red itchy skin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Alpha-1 adrenergic receptor (guinea pig)
Target ID: Muscarinic acetylcholine receptors (guinea pig)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Colofac

Approved Use

Colofac is used to treat symptoms of irritable bowel syndrome and similar problems.

Launch Date

1978
Palliative
Colofac

Approved Use

This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis.

Launch Date

1978
Palliative
Colofac

Approved Use

This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis

Launch Date

1978
PubMed

PubMed

TitleDatePubMed
Drug therapy options for patients with irritable bowel syndrome.
2001 Jul
The antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassay (FPIA)--studies on the toxicological analysis of urine by FPIA and GC-MS.
2001 Jul-Aug
Identification of mebeverine acid as the main circulating metabolite of mebeverine in man.
2002 Jun 20
On-line micellar electrokinetic chromatography-mass spectrometry: feasibility of direct introduction of non-volatile buffer and surfactant into the electrospray interface.
2003 Jun 6
Atmospheric pressure photoionization for enhanced compatibility in on-line micellar electrokinetic chromatography-mass spectrometry.
2005 Aug 15
Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial.
2005 Aug 20
Potentiometric flow injection analysis of mebeverine hydrochloride in serum and urine.
2005 Jan 4
Generic and brand-name drugs. Are different criteria sufficiently taken into account before granting market authorisation?
2006
Formulation of an antispasmodic drug as a topical local anesthetic.
2006 Dec 1
A validated chiral HPLC method for the determination of mebeverine HCl enantiomers in pharmaceutical dosage forms and spiked rat plasma.
2006 Feb
Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases.
2006 May
"My patients are the sickest".
2006 May
Colon-specific drug delivery for mebeverine hydrochloride.
2007 Dec
[Efficacy of duspatalin in the treatment and prophylaxis of postcholecystectomic syndrome].
2008
Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome.
2008 Apr
Serotonin receptor modulators in the treatment of irritable bowel syndrome.
2008 Feb
Evaluation of the Birmingham IBS symptom questionnaire.
2008 Jul 23
Spectrophotometric determination of benzydamine HCl, levamisole HCl and mebeverine HCl through ion-pair complex formation with methyl orange.
2008 Mar
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
2008 May
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.
2008 Nov 13
Drug use in children: cohort study in three European countries.
2008 Nov 24
Development of membrane selective electrode for determination of the antipsychotic sulpiride in pharmaceuticals and urine.
2009
[The effectiveness of spasmolytic therapy in chronic acalculous cholecystitis].
2009
[How to raise efficacy of gastroesophageal reflux disease treatment].
2009
Psychological associations of irritable bowel syndrome besides panic disorder: an often overlooked reality.
2009
[A method for non-medicamentous treatment of irritated bowel syndrome].
2009 May-Jun
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Validated HPLC determination of the two fixed dose combinations (chlordiazepoxide hydrochloride and mebeverine hydrochloride; carvedilol and hydrochlorothiazide) in their tablets.
2010 Jul-Aug
Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial).
2010 Nov 18
Topical piroxicam in vitro release and in vivo anti-inflammatory and analgesic effects from palm oil esters-based nanocream.
2010 Nov 4
Autoimmune hepatitis triggered by nitrofurantoin: a case series.
2010 Sep 23
Presentations of perforated colonic pathology in patients with polymyalgia rheumatica: two case reports.
2010 Sep 6
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Sample Use Guides

One tablet (135 mg) three times a day. This may be gradually reduced after a few weeks when the desired effect has been obtained. The tablets are best taken 20 minutes before meals.
Route of Administration: Oral
In Vitro Use Guide
Mebeverine (10^5-10^4 M) suppressed the amplitude of the action potential and lengthened the time between stimulation and the top of the response in non-myelinated fibres of the vagus nerve.
Name Type Language
MEBEVERINE HYDROCHLORIDE
MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
Mebeverine hydrochloride [WHO-DD]
Common Name English
MEBEVERINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
MEBEVERINE HYDROCHLORIDE [USAN]
Common Name English
MEBEVERINE HCL
Common Name English
MEBEVERINE HYDROCHLORIDE [MI]
Common Name English
BENZOIC ACID, 3,4-DIMETHOXY-, 4-(ETHYL(2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)BUTYL ESTER, HYDROCHLORIDE
Common Name English
4-(ETHYL(P-METHOXY-.ALPHA.-METHYLPHENETHYL)AMINO)BUTYL VERATRATE HYDROCHLORIDE
Common Name English
MEBEVERINE HYDROCHLORIDE [MART.]
Common Name English
NSC-169101
Code English
CSAG-144
Code English
Classification Tree Code System Code
NCI_THESAURUS C66880
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C73596
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY
MESH
C005096
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY
RXCUI
235827
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
220-400-0
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY
CAS
2753-45-9
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY
MERCK INDEX
m7108
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY Merck Index
FDA UNII
15VZ5AL4JN
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY
EVMPD
SUB03102MIG
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY
ChEMBL
CHEMBL282121
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY
PUBCHEM
17683
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID1045372
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY
NSC
169101
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY
SMS_ID
100000086181
Created by admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
PRIMARY